SP-102 + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
69
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Lumbosacral Radicular Pain
Conditions
Lumbosacral Radicular Pain
Trial Timeline
Dec 8, 2017 → Jan 6, 2022
NCT ID
NCT03372161About SP-102 + Placebo
SP-102 + Placebo is a phase 3 stage product being developed by Scilex Holding for Lumbosacral Radicular Pain. The current trial status is completed. This product is registered under clinical trial identifier NCT03372161. Target conditions include Lumbosacral Radicular Pain.
Hype Score Breakdown
Clinical
27
Activity
18
Company
2
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03372161 | Phase 3 | Completed |
Competing Products
5 competing products in Lumbosacral Radicular Pain
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VX-548 + Placebo | Vertex Pharmaceuticals | Phase 2 | 51 |
| BIIB074 + Placebo | Biogen | Phase 2 | 49 |
| CNV1014802 + Placebo | Biogen | Phase 2 | 49 |
| BIIB074 | Biogen | Phase 2 | 49 |
| SP-102 | Scilex Holding | Phase 2 | 44 |